Blood cancer drug's secret solved
24 February, 2016Researchers from the Walter and Eliza Hall Institute have solved a mystery about how a promising new class of anticancer drugs works.
Two new prostate cancer trials funded
23 February, 2016Prostate Cancer Foundation Australia (PCFA) and the Movember Foundation are funding two new clinical trials that will potentially revolutionise the way prostate cancers are monitored and treated.
Wristband for monitoring movement disorders
18 February, 2016Global Kinetics Corporation has partnered with the Parkinson's Institute and Clinical Center to provide access to its mobile health technology for monitoring movement disorders.
Prescient breast cancer trial progresses under a new CEO
17 February, 2016Prescient Therapeutics has marked two key milestones — the dosing of the last patient in the escalation stage of its Phase Ib breast cancer trial and the appointment of a new CEO.
An early step in type 1 diabetes development
12 February, 2016An American-Australian research team has identified what may be the initial target of the immune response that causes type 1 diabetes.
TBG Diagnostics relisted on ASX
03 February, 2016TBG Diagnostics, formerly known as Progen Pharmaceuticals, has been relisted on the ASX under the code TDL.
US patent granted for IMP731 antibody
28 January, 2016The United States Patent and Trademark Office has granted a patent for the IMP731 antibody, owned by Australian biotech company Prima BioMed.
Parkinson's progress halted in study patients
27 January, 2016Shares in Living Cell Technologies leapt over 40% after the biotechnology company revealed that it had halted the progression of Parkinson's disease in four study participants.
Melanoma study to be conducted across Australia
27 January, 2016Prima BioMed has announced the Gallipoli Medical Research Foundation as the first clinical trial site for TACTI-mel, a Phase I study into melanoma treatment with lead compound IMP321.
Imugene to develop mimotope-based immunotherapies
21 January, 2016Imugene has announced the extension of its partnership with the Medical University of Vienna to discover and develop new mimotope-based immunotherapies against validated and new oncology targets.
Putting a hex on leukaemia
18 January, 2016Scientists have discovered that targeting a protein called Hhex could cure acute myeloid leukaemia (AML) in preclinical disease models and could also be a key target for new therapies for human leukaemia.
Imugene patent granted in Europe
18 December, 2015Imugene has received a Notice of Grant from the European Patent Office for Patent Application 10744895.3, which protects the company's HER-Vaxx cancer immunotherapy.
NFMRI announces 2016 grant recipients
04 December, 2015The National Foundation for Medical Research and Innovation has announced its 2016 grant recipients, supporting researchers from across the country in the advancement of their medical innovations.
Could we kill two diseases with one campaign?
04 December, 2015 by Graeme O'NeillBritish researchers have proposed that the WHO's planned mass treatment campaign to eradicate the tropical disease yaws from the planet by 2020 should be integrated with a WHO-led project to eliminate another common disease of the world's poor — trachoma — with the same deadline.
Identifying Alzheimer's genes
02 December, 2015In a study led by The Australian National University, scientists have identified a network of nine genes that play a key role in the onset of Alzheimer's disease.
